{
    "Trade/Device Name(s)": [
        "Dexcom G6 Glucose Program Continuous Glucose Monitoring (CGM) System"
    ],
    "Submitter Information": "Dexcom, Inc.",
    "510(k) Number": "K193642",
    "Predicate Device Reference 510(k) Number(s)": [
        "K192787"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QDK"
    ],
    "Summary Letter Date": "December 27, 2019",
    "Summary Letter Received Date": "December 30, 2019",
    "Submission Date": "December 27, 2019",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated continuous glucose monitoring system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Dexcom G6 sensor/applicator",
        "Dexcom G6 transmitter",
        "Dexcom Glucose Program mobile application (Android/iOS)"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction"
    ],
    "Methodologies": [
        "Continuous glucose monitoring"
    ],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Transmitter",
        "Mobile application"
    ],
    "Document Summary": "FDA 510(k) summary for Dexcom G6 Glucose Program CGM System for continuous glucose monitoring using amperometric sensor and mobile app",
    "Indications for Use Summary": "Real-time continuous glucose monitoring system indicated for management of diabetes in persons aged 2 years and older, intended to replace fingerstick blood glucose testing for diabetes treatment decisions, and to autonomously communicate with digitally connected devices.",
    "fda_folder": "Clinical Chemistry"
}